Windamere is primarily focused on seed and early-stage investments in product-focused healthcare companies. The principal areas of focus include:

• Emerging Pharmaceuticals. Clinical-stage or late preclinical-stage drug compounds with differentiable positions in their respective market segments.
  
  
• Specialty Pharmaceuticals. Commercial and often late clinical-stage drug products with distinct market segments or disease areas that can be promoted to a specialty physician audience with a focused selling organization.
  
  
• Medical Devices. Technologies that provide significant clinical benefits over existing medical practices, offer cost-effective improvements in clinical care for a sizable patient population, and have a reasonable FDA regulatory pathway.